Lapisteride
Clinical data | |
---|---|
Routes of administration | Oral[1] |
ATC code | None |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 142139-60-4 |
PubChem (CID) | 9847295 |
ChemSpider | 8023009 |
UNII | T50SJ23G82 |
Chemical and physical data | |
Formula | C29H40N2O3 |
Molar mass | 464.6395 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Lapisteride (INN; CS-891) is a dual inhibitor of both isoforms of the enzyme 5α-reductase.[2] It was under investigation for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia,[2][3] but was never marketed.
See also
References
- ↑ Yada S, Ohya M, Ohuchi Y, et al. (April 2003). "Solid phase transition of CS-891 enantiotropes during grinding". International Journal of Pharmaceutics. 255 (1-2): 69–79. doi:10.1016/S0378-5173(03)00084-X. PMID 12672603.
- 1 2 Niiyama S, Kojima K, Hamada T, Happle R, Hoffmann R (December 2000). "The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles". European Journal of Dermatology. 10 (8): 593–5. PMID 11125319.
- ↑ Bernan; British Pharmacopoeia Commission (February 2002). British Approved Names 2002. The Stationery Office. p. 157. ISBN 978-0-11-322558-3. Retrieved 17 November 2011.
This article is issued from Wikipedia - version of the 11/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.